Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, has released a new edition of its “State of Rural Hospitals and Cardiovascular Care” report. The report is designed to provide rural healthcare leaders, policymakers, and community-based organizations with actionable insights to improve cardiovascular care quality and outcomes in underserved areas.
The updated report identifies critical challenges facing rural healthcare, including shortages of specialists and physicians, limited broadband access, and a higher prevalence of cardiovascular disease risk factors among rural populations. These factors contribute to significant disparities in cardiovascular outcomes between rural and urban areas. To address these issues, the report presents a four-part care model focused on upskilling primary care clinicians, advancing care through epigenetic-genetic testing, implementing population-wide health strategies, and integrating remote care options in rural communities.
According to the company, the revised report also emphasizes the role of emerging technologies, such as virtual cardiac care and precision-medicine testing, in strengthening early detection, improving access, and enabling personalized care. By leveraging these tools, rural healthcare providers can better manage cardiovascular disease despite limited resources.
The release of this report comes at a time when cardiovascular disease remains the leading cause of death in the United States, with rural populations facing disproportionately higher mortality rates. The report’s findings are intended to guide strategic planning and resource allocation for rural health systems, potentially reducing the burden of cardiovascular disease in these communities.
For more information about the report, visit this link.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that aims to make cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company leverages its proprietary AI-driven Integrated Genetic-Epigenetic Engine to develop and commercialize clinical tests for cardiovascular disease.
The latest news and updates regarding CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.
